Summit Therapeutics shares are higher today, May 5, 2026, in what appears to be a rebound trade following the stock’s steep decline late last week around an ivonescimab HARMONi-3 update that failed to meet investors’ “beat-and-raise” expectations. With no fresh, company-issued headline clearly driving the tape this morning, price action looks consistent with dip-buying and positioning ahead of upcoming oncology catalysts and regulatory milestones. (ts2.tech)

SMMT carries unusually high short interest for a large-cap biotech, which can mechanically intensify upside moves when the stock turns higher and short sellers reduce exposure. As of March 31, 2026, short interest was about 34.56 million shares, roughly 29.52% of the public float, creating conditions where a modest rebound can be amplified by incremental covering. (marketbeat.com)

The central bull/bear debate remains ivonescimab. Summit has an FDA Biologics License Application under review for ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after prior TKI therapy, with a PDUFA goal action date of November 14, 2026—keeping a clear, date-certain catalyst on the horizon even as investors digest mixed trial updates. (sec.gov)

Near-term, traders will be watching whether the rebound holds as attention shifts to higher-profile data readouts and presentations expected later in 2026. Any additional disclosures around trial endpoints, safety, or timelines—especially those tied to late-stage NSCLC programs—could quickly reset expectations and volatility in either direction. (marketchameleon.com)